The role of Hedgehog signaling pathway in head and neck squamous cell carcinoma
P Cierpikowski, A Leszczyszyn, J Bar - Cells, 2023 - mdpi.com
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading malignancy
worldwide, with a poor prognosis and limited treatment options. Molecularly targeted …
worldwide, with a poor prognosis and limited treatment options. Molecularly targeted …
Oral cancer stem cells: Therapeutic implications and challenges
LA Shahoumi - Frontiers in Oral Health, 2021 - frontiersin.org
Head and neck squamous cell carcinoma (HNSCC) is currently one of the 10 most common
malignancies worldwide, characterized by a biologically highly diverse group of tumors with …
malignancies worldwide, characterized by a biologically highly diverse group of tumors with …
[HTML][HTML] Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors
P Bossi, PA Ascierto, N Basset-Seguin, B Dreno… - Critical Reviews in …, 2023 - Elsevier
Basal cell carcinoma (BCC), the most common type of skin cancer, is characterized by
aberrant activation of the hedgehog molecular pathway. Systemic therapy is indicated when …
aberrant activation of the hedgehog molecular pathway. Systemic therapy is indicated when …
Comprehending the crosstalk between Notch, Wnt and Hedgehog signaling pathways in oral squamous cell carcinoma-clinical implications
Background Oral squamous cell carcinoma (OSCC) is a malignant oral cavity neoplasm that
affects many people, especially in developing countries. Despite several advances that have …
affects many people, especially in developing countries. Despite several advances that have …
Integrated radiogenomics analyses allow for subtype classification and improved outcome prognosis of patients with locally advanced HNSCC
Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) may
benefit from personalised treatment, requiring biomarkers that characterize the tumour and …
benefit from personalised treatment, requiring biomarkers that characterize the tumour and …
Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells
R Kleszcz, M Frąckowiak, D Dorna… - International Journal of …, 2023 - mdpi.com
The Wnt/β-catenin, EGFR, and PI3K pathways frequently undergo upregulation in head and
neck squamous carcinoma (HNSCC) cells. Moreover, the Wnt/β-catenin pathway together …
neck squamous carcinoma (HNSCC) cells. Moreover, the Wnt/β-catenin pathway together …
Hedgehog inhibitor induction with addition of concurrent superficial radiotherapy in patients with locally advanced basal cell carcinoma: a case series
JP Weissman, W Samlowski, R Meoz - The Oncologist, 2021 - academic.oup.com
Background Locally advanced basal cell cancer is a rare and challenging clinical problem.
Historically, these patients were treated with aggressive surgery or radiotherapy. Most …
Historically, these patients were treated with aggressive surgery or radiotherapy. Most …
Small-molecule drug repurposing to target DNA damage repair and response pathways
For decades genotoxic therapy has been a mainstay in the treatment of cancer, based on
the understanding that the deregulated growth and genomic instability that drive malignancy …
the understanding that the deregulated growth and genomic instability that drive malignancy …
[HTML][HTML] Pathophysiological relationship between hypoxia associated oxidative stress, Epithelial-mesenchymal transition, stemness acquisition and alteration of Shh …
Oral sub-mucous fibrosis (OSF) is a pathophysiological state of oral cavity or oropharynx
having a high chance of conversion to oral squamous cell carcinoma (OSCC). It involves …
having a high chance of conversion to oral squamous cell carcinoma (OSCC). It involves …
The non-apoptotic function of Caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer
R Mandal, M Raab, F Rödel, A Krämer… - Cellular and Molecular …, 2022 - Springer
Cervical cancer is the fourth most frequently diagnosed and fatal gynecological cancer. 15–
61% of all cases metastasize and develop chemoresistance, reducing the 5-year survival of …
61% of all cases metastasize and develop chemoresistance, reducing the 5-year survival of …